Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

A major health initiative worth £85million has been unveiled by the Government, vowing to revolutionise obesity treatment for ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

Around 28% of UK adults are classified as obese according to a Healthy Survey for England. Roughly one in three children ...

The report highlights a significant market shift, positioning gastric space-occupying devices as a crucial and effective alternative for patients who have not achieved success with traditional ...

The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Taxpayers are paying for unhealthy junk food sold to needy Americans through welfare benefits that contribute to chronic ...

The US government is approaching the study of obesity all wrong.

Restricting SNAP purchases stigmatizes low-income people and sends the message they are not worthy of making the same choices ...

Neuroscientist Dr. Randy J. Nelson explores how artificial light at night disrupts our bodies, from immune health to mood.